Abstract 836
Background
In this retrospective cohort study based in Taiwan, we reported the current epidemiology of patients with multiple myeloma and analyzed the effect of bortezomib-based therapy on clinical outcomes.
Methods
We identified 5726 patients with newly diagnosed multiple myeloma (MM) between 2007 and 2015 in Taiwan. Privileges data from the National Health Institute Research Database was used, as it is made readily available to the public in electronic format for research purposes.
Results
Among them, from January 2007 to October 2011, there were 1116 multiple myeloma patients (control group: bortezomib as non-first-line drug), and there were 4610 multiple myeloma patients from November 2011 to December 2015.The results showed that in the case group the proportion of hospital deaths in the future was 15.73% (702/4464), while the proportion of hospital deaths in the control group was 19.80% (221/1116). The patient with first-line with bone marrow transplantation, the first-line without bone marrow transplantation, the non-first-line with bone marrow transplantation, the probability of hospital death risk was 0.387 times higher than that of the non-first-line without bone marrow transplantation) (P < 0.001) ), 0.681 times (P < 0.001), 0.724 times (P = 0.035).
Conclusions
In conclusion, our study showed that the first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma was better than the non-first line. To provide the most representative data on Bortezomib treatment results of MM patients achievable in Taiwan, we could prospectively collect nationwide data including detailed information. This could not only provide stage-stratified survival and disease-specific survival rates but also help to identify better clinical effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract